文献速递消化道出血

阿司匹林、低剂量利伐沙班或二者联合患者中重大消化道出血的发生率与预测因素:COMPASS随机对照试验的二次分析

Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial.
PubMed 文献 · Aliment Pharmacol Ther · 2024-07-01

该研究为COMPASS随机对照试验的二次分析,纳入27,395例患者,比较阿司匹林100 mg每日、利伐沙班2.5 mg每日两次联合阿司匹林、或利伐沙班5 mg每日两次的消化道出血发生率。结果显示联合组年发生率为801.7/10万,阿司匹林组为372.3/10万;年龄≥75岁、消化性溃疡病、肝病、高血压、吸烟与总体消化道出血相关,肾病与上消化道出血相关,憩室病与下消化道出血相关。

要点

  • 利伐沙班2.5 mg每日两次联合阿司匹林组消化道出血年发生率为801.7/10万,阿司匹林组为372.3/10万。
  • 年龄≥75岁(OR 4.16)、消化性溃疡病(OR 1.57)、肝病(OR 2.09)、高血压(OR 1.42)、吸烟(OR 1.85)与总体消化道出血相关。
  • 利伐沙班联合阿司匹林与下消化道出血的关联(OR 2.82)强于上消化道出血(OR 1.86)。

核心结论

  • 研究确立了低剂量直接口服抗凝药使用者的消化道出血发生率并识别了风险因素,新发现的风险因素包括当前或既往吸烟和憩室病。
  • 未来研究应旨在验证这些风险因素。

研究设计与样本

  • COMPASS随机对照试验数据的二次分析,患者接受阿司匹林100 mg每日、利伐沙班2.5 mg每日两次联合阿司匹林、或利伐沙班5 mg每日两次。
  • 2013年至2016年在602个中心随访,共纳入27,395例患者。
  • 采用多变量逻辑回归计算潜在暴露因素的比值比(OR)和95%置信区间。

主要发现

  • 利伐沙班2.5 mg每日两次联合阿司匹林组消化道出血年发生率为801.7/10万,阿司匹林组为372.3/10万。
  • 年龄≥75岁 vs. 55-64岁与总体消化道出血相关(OR 4.16,95%CI 2.53-6.82)。
  • 消化性溃疡病(OR 1.57,95%CI 1.01-2.44)、肝病(OR 2.09,95%CI 1.01-4.33)、高血压(OR 1.42,95%CI 1.04-1.94)、吸烟(OR 1.85,95%CI 1.26-2.73)与总体消化道出血相关。
  • 肾病(OR 1.68,95%CI 1.12-2.51)与上消化道出血显著相关,憩室病(OR 3.75,95%CI 1.88-7.49)与下消化道出血相关。
  • 阿司匹林联合利伐沙班与下消化道出血的关联(OR 2.82,95%CI 1.64-4.84)强于上消化道出血(OR 1.86,95%CI 1.18-2.92)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来研究应旨在验证这些风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of major gastrointestinal bleeding (GIB) in patients on low-dose direct-acting oral anticoagulants (DOACs) is relatively unknown. Estimates from randomised controlled trials (RCTs) are lacking. AIMS: To assess GIB incidence and predictors from RCT data of patients on aspirin, low-dose rivaroxaban, or both. METHODS: This was a secondary analysis of RCT data wherein patients received aspirin 100 mg daily and rivaroxaban 2.5 mg b.d., aspirin alone, or rivaroxaban 5 mg b.d. Patients were followed from 2013 to 2016 at 602 centres. Outcomes included overall, upper, and lower GIB. We employed multivariable logistic regression to yield odds ratios (ORs) and 95% confidence intervals for potential exposures. RESULTS: Among 27,395 patients, the annual incidence of GIB on rivaroxaban 2.5 mg b.d. with aspirin was 801.7 per 100,000 compared with 372.3 in 100,000 for aspirin. Age (OR 4.16, 2.53-6.82 for ≥75 vs. 55-64), peptic ulcer disease (PUD, OR 1.57, 1.01-2.44), liver disease (OR 2.09, 1.01-4.33), hypertension (OR 1.42, 1.04-1.94), and smoking (OR 1.85, 1.26-2.73) were associated with overall GIB. Kidney disease (OR 1.68, 1.12-2.51) was significantly associated with upper GIB, whereas diverticular disease (OR 3.75, 1.88-7.49) was associated with lower GIB. Addition of rivaroxaban to aspirin was associated more with lower GIB (OR 2.82, 1.64-4.84) than upper GIB (OR 1.86, 1.18-2.92). CONCLUSIONS: We established incidences and identified risk factors for GIB in users of low-dose DOACs. Novel risk factors included current or former smoking and diverticulosis. Future studies should aim to validate these risk factors.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Forbes N, Yi Q, Moayyedi P, et al. Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial. Aliment Pharmacol Ther. 2024. PMID: 38952045. doi:10.1111/apt.18139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。